Lyell Immunopharma stock. Company profile and Nasdaq listing.

Lyell Immunopharma stock reflects a clinical-stage cell therapy company with a Nasdaq listing and a U.S. investor base.

Lyell Immunopharma (ISIN US55083R1041) is a clinical-stage biotechnology company focused on cell therapies for cancer, and its shares trade on Nasdaq under the ticker LYEL.

Business focus

The company works on engineered T-cell therapies designed to improve durability and effectiveness in solid tumors and hematologic cancers. Its platform approach centers on developing cell therapies with stronger persistence, better tumor activity, and more consistent manufacturing characteristics.

Market setup

Lyell Immunopharma is a U.S.-listed stock, which keeps it within the investor frame that follows Nasdaq-traded biotechnology names and SEC-reporting issuers. For investors, the central question remains the companys ability to translate its platform into clinical and regulatory progress.

Therapy platform

A representative product effort is the companys cell therapy research and development pipeline, which is built around next-generation T-cell engineering rather than a single consumer product. That keeps the story tied to clinical data, trial design, and eventual manufacturing scale.

Stock context

As of July 8, 2026, the share price was not included here. Lyell Immunopharma trades on Nasdaq in USD.

Lyell Immunopharma facts

• Company: Lyell Immunopharma, Inc.
• ISIN: US55083R1041
• Ticker: LYEL
• Exchange: Nasdaq
• Sector / Industry: Biotechnology